Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.5 USD | 0.00% |
|
+1.88% | -36.95% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.95% | 187M | |
+7.23% | 217B | |
+11.31% | 188B | |
+28.94% | 153B | |
+32.00% | 112B | |
-0.30% | 62.84B | |
+16.09% | 52.35B | |
+0.80% | 49.33B | |
+1.23% | 35.4B | |
+23.40% | 30.9B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Earnings Flash (NPCE) NEUROPACE Posts Q1 Revenue $14.5M, vs. Street Est of $12.2M